Hypothalamic Hamartomas: Correlation of MR Imaging and Spectroscopic Findings with Tumor Glial Content

Methods

Fourteen patients (5 males, 9 females; ranging from 2 to 17 years of age) who underwent transcallosal resection of hypothalamic hamartoma for refractory epilepsy at this facility between June 2003 and February 2004 were included in this series. These patients had previously undergone imaging and clinical evaluations at other centers and were referred to this center for surgical therapy. Imaging and clinical data were reviewed at this center to confirm the diagnosis of hypothalamic hamartoma.

Results

All hamartomas had a sessile attachment to the hypothalamus, and no pedunculated lesions were noted in this series. Histologic evaluation of the hamartomas demonstrated varying levels of neuronal and glial content. Some tumors exhibited a heterogeneous appearance with small nests of neurons or glial cells on a more homogeneous cellular background. Neuronal elements when present were characteristic, typically smaller than the larger ganglion cells that predominate in the normal hypothalamus. Dysplastic neurons were rarely seen. Glial elements were readily distinguished from astrocytoma, demonstrating small bland nuclei, no atypia or hypercellularity, and little or no proliferative activity on MIB-1 testing. Examples of predominately neuronal and predominately glial histology are given in Fig 1, with corresponding MR spectra and T2 images.

• Download figure
• Open in new tab
• Download powerpoint

Fig 1.

Photomicrograph (H&E stain) from predominantly neuronal hypothalamic hamartoma (A) with corresponding single voxel MR spectrum (3T) and axial T2-weighted image (B, -C). The mI peak is moderately elevated and tumor is slightly hyperintense relative to gray matter on T2-weighted images. Also shown are a photomicrograph from a predominately glial hamartoma (D) with corresponding spectrum (1.5T) and T2-weighted images (E,-F). The mI peak is markedly elevated, and the lesion is very hyperintense in comparison to gray matter. Cho is mildly elevated, and NAA is reduced in both cases.

Data from single voxel spectroscopy of the hamartomas demonstrated significant differences in NAA/Cr (P < .001), Cho/Cr (P < .001), and mI/Cr ratios (P < .001) when compared with similar ratios in normal gray matter of the amygdala (Fig 2). NAA ratios were decreased, whereas mI and Cho ratios were increased compared with normal controls. Although all mI ratios were significantly higher than normal, a subgroup was retrospectively identified to be markedly higher than others. Values for mI were then plotted against the neuropathology rating scale. Except for 1 outlier, higher mI/Cr ratios corresponded to increased glial content within the tumor (Fig 3). Correlation of mI/Cr against pathologic grade yielded a linear regression coefficient of 0.74 (P = .004). Removal of the 1 outlier from the dataset increased the correlation coefficient to 0.84 (P = .0006). No association of NAA/Cr or of Cho/Cr with pathologic grade was found.

• Download figure
• Open in new tab
• Download powerpoint

Fig 2.

Graph shows the comparison of spectral ratios within tumor and normal gray matter. A significant decrease is noted in NAA/Cr in the hypothalamic hamartomas compared with normal controls. Significant increases are seen in mI/Cr and Cho/Cr. Horizontal dashes represent 95% confidence intervals.

• Download figure
• Open in new tab
• Download powerpoint

Fig 3.

Scatterplot shows individual mI/Cr ratios of hypothalamic hamartomas versus 6-point pathology rating scale (1 = mostly neuronal, 6 = mostly glial). Samples exhibit increased mI concentrations with increasing glial content. One relatively neuronal sample (pathology rating, 2) demonstrates an anomalously high mI/Cr = 1.1.

Appearance of the hamartomas on T2-weighted images also varied. Some lesions were only mildly hyperintense to gray matter on T2 sequences whereas others were notably higher in intensity. The ratio of intensity of hamartoma to gray matter ranged from 1.05 to 1.82 (mean, 1.40; standard deviation, 0.22). Four of the hamartomas in our series exhibited a heterogeneous appearance with areas of varying intensity within the lesion. Intensity ratios were measured with region of interest encompassing most of the lesion without measuring individual areas of heterogeneity. T2 intensity ratios were also plotted against the rating scale of the neuropathologist, and except for the same sample seen as an outlier with mI/Cr, a similar relationship was again noted: Higher T2 intensities correlated with tumors of increased glial content on pathologic evaluation (Fig 4). Correlation analysis yielded a linear correlation coefficient of 0.46 (P =.1), which increased to 0.74 (0.003) when the outlier was removed.

• Download figure
• Open in new tab
• Download powerpoint

Fig 4.

Graph shows relative T2 hyperintensity of hypothalamic hamartomas versus 6-point pathology rating scale (1 = mostly neuronal, 6 = mostly glial). Data demonstrate increasing T2 intensity with increased tumor glial content. A sample with pathology rating of 2 and an anomalously high T2 ratio of 1.8 is the same sample seen as an outlier in Fig 3 and discussed in the text.

Clinical features of the patients were also examined against the fraction of glial component for correlation. Features including age at onset of epilepsy, duration of epilepsy, severity of epilepsy, presence of precocious puberty, and cognitive function were plotted against the 6-point pathology rating scale. No clear clinical associations existed with the degree of glial abundance on pathology in this series. Currently, this aspect of the pathology (and therefore that of the MR spectroscopy findings) does not prove to be a discriminator for clinical subgroups within the hypothalamic hamartoma spectrum.

Discussion

Prior studies have described the MR imaging appearance and MR spectroscopic properties of hypothalamic hamartomas. Signal intensity on T2-weighted images in published series has varied from isointense to hyperintense when compared with normal gray matter.^4–10 Our finding of progressive T2 hyperintensity with increasing glial content sheds light on this variability of T2 appearance in prior studies.

Previous authors have also described the proton MR spectroscopic properties of hypothalamic hamartomas. Wakai et al¹⁴ found decreased NAA/Cr with no alteration of other metabolites in a single case study. Tasch et al¹⁵ also confirmed these findings in a spectroscopic study including 5 patients. More recent studies using short TE spectroscopic sequences have found an increase in mI in addition to the NAA reduction. Martin et al⁷ described increased mI in a hypothalamic hamartoma in a single case study. Freeman et al⁹ recently confirmed this finding of increased mI levels in a study that included 19 hamartomas. Our data are consistent with these findings.

One area of discordance seen in our study when compared with some of the previous literature is a significant increase in Cho/Cr ratios within hamartomas compared with normal gray matter of the amygdala. In the recent literature, an increase in Cho concentration within hypothalamic hamartomas compared with gray matter of the thalamus but not of the amygdala was reported by Martin et al,⁷ and a similar increase was reported by Akai et al.¹⁶ Freeman et al⁹ found no increase in Cho concentration within hypothalamic hamartomas in their series when compared with thalamic gray matter, though differences in Cr concentration between hamartoma and gray matter of the thalamus appear to be associated with some elevation of hamartoma Cho/Cr ratios compared with those in the thalamus in their data. Some of these differences could thus be methodologic, reflecting differences between Cho and Cr concentrations in normal gray matter in different parts of the brain as well as differences between concentrations derived from spectroscopic modeling and concentration ratios. Note also that although increased Cho has been associated with higher grade gliomas, this finding can also be seen in benign histologies.^17,18

Alterations in cerebral metabolite concentrations detectable with MR spectroscopy have been associated with several pathologic conditions. Decreased NAA is generally identified with neuronal loss, and elevated Cho has been associated with rapid membrane turnover.^19–21 Changes in these metabolites are associated with a number of cerebral pathologies. At spectral resolutions achieved in ¹H-MR spectroscopy, the peak commonly associated with mI contains contributions from glycine and other macromolecular metabolites.²² Prior studies have associated increased mI with gliosis^20,22 and also with osmotic shifts, reflecting the putative role of mI as an astrocytic osmolyte.²³ Elevated mI has been reported in association with a broad spectrum of conditions, including glial neoplasms,^24,25 multiple sclerosis and clinically isolated syndromes,²⁶ stroke,²⁷ neonatal encephalopathy,²⁸ and Alzheimer disease.²⁹ Our findings extend these observations by identifying an association between both mI level and average T2 signal intensity versus glial fraction within hypothalamic hamartomas.

Although in our series, mI ratio and T2 signal intensity are both positively correlated with increasing glial component within a lesion, several sources of heterogeneity are present in our measurements. The most significant include uncorrected partial volume effects within the spectroscopic voxel and sampling error related to piecemeal removal of only a portion of the hamartoma during transcallosal resection. Additional lesser sources of variability include intrinsic heterogeneity with a given lesion, apparent at histopathologic review and also on the T2-weighted images. An additional source of potential bias arises from the inclusion in our series of only patients selected for surgical therapy for refractory seizures. The pooling of spectroscopic ratio data from 1.5T and 3T imaging systems is also a potential source of heterogeneity; however, the conclusions of this study are separately supported by data from each of the 2 field strengths.

Beyond these sources of heterogeneity, 1 relatively neuronal sample demonstrated greater than expected mI ratio and excess T2 hyperintensity. This outlier exhibited mild heterogeneity on T2-weighted images. Even on retrospective review of the pathologic sample and the spectroscopic data, discordance was still present. We believe that surgical sampling bias is the most likely explanation for this outlier.

Although MR spectroscopy does provide a valuable additional probe of cerebral pathology, supplementing the information available from imaging alone, the results are not highly specific. In particular, elevation of mI can also be seen in some cases of low-grade glioma, even without associated elevation in Cho.^25,30 Thus, the spectral signature alone cannot reliably differentiate hypothalamic hamartoma from glioma, although such data can supplement contrast-enhanced imaging and repeated scans in excluding glioma.

Conclusion

Our data reveal a correlation between both mI concentration and T2 signal intensity of hypothalamic hamartomas versus glial fraction as determined by histopathology. No association with clinical subgroups was found in this series; however, these imaging differences could potentially provide a basis for more accurate selection of patients for therapy techniques in the future.